14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
FMAC vs IPOD: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 16, 2026, IPOD (IPOD) is the stronger overall head-to-head candidate over FMAC (FMAC) in the Tradestie Institutional Equity Comparison Engine, winning 9–0 core matrix metrics and 3–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). FMAC carries a Unified Composite Score of 56.2/100 (HOLD) at $10.11 (N/M Forward P/E, N/A operating margin), whereas IPOD carries 58.0/100 (HOLD) at $10.42 (N/M Forward P/E, 0.0% operating margin).
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on FMAC vs IPOD. Trailing 12-month operating profitability (FMAC N/A vs IPOD 0.0%) and valuation multiples (FMAC N/M vs IPOD N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Shell Companies value chain with $210.0M market capitalization and 0.0% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ FMAC vs IPOD Key Questions & Quantitative Answers
As of Nov 16, 2026, IPOD (IPOD) is the stronger overall head-to-head candidate over FMAC (FMAC) in the Tradestie Institutional Equity Comparison Engine, winning 9–0 core matrix metrics and 3–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). FMAC carries a Unified Composite Score of 56.2/100 (HOLD) at $10.11 (N/M Forward P/E, N/A operating margin), whereas IPOD carries 58.0/100 (HOLD) at $10.42 (N/M Forward P/E, 0.0% operating margin). Technically, FMAC sits in a Neutral phase (RSI N/A, UNCLASSIFIED options structure) and IPOD sits in a Neutral phase (RSI N/A, UNCLASSIFIED options structure).
IPOD leads the Growth & Scale pillar: FMAC posts N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin), compared with IPOD at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, FMAC generates N/A in USD-normalized revenue versus N/A for IPOD. In operating R&D and SG&A reinvestment, FMAC deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for IPOD.
IPOD screens cheaper on headline valuation multiples. FMAC trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas IPOD trades at N/M Forward P/E, 39.9x Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against FMAC (N/A ROE) versus IPOD (0.0% ROE) capital efficiency.
In options market volatility and institutional positioning, FMAC carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.04β · 5% Vol realized risk). By comparison, IPOD carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.00β · 2% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.